Amy W. Schulman is the Chief Executive Officer of Lyndra, Inc. In 2014, she joined Polaris Partners’ Boston office, simultaneously assuming the role of CEO of Arsia Therapeutics, a Polaris-backed company which was acquired by Eagle Pharmaceuticals in November 2016. In July 2015, Amy co-founded Lyndra, where she is CEO. Amy is the recipient of numerous awards and distinctions including: Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, Fortune Magazine’s 2013 50 Most Powerful Women in Business, The American Lawyer’s 2013 Top 50 Innovators, and The National Law Journal’s 2013 100 Most Influential Lawyers in America. She is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Amy earned her JD from Yale Law School in 1989. She serves as the Executive Chair of SQZ Biotech and Suono Bio and is director of Alnylam Pharmaceuticals and Ironwood Pharmaceuticals. In addition, Amy serves as a director of Blue Buffalo and the Whitehead Institute.